Paclitaxel-induced peripheral neuropathy in male rats attenuated by calmangafodipir, a superoxide dismutase mimetic

J Pharmacol Sci. 2025 Jan;157(1):8-11. doi: 10.1016/j.jphs.2024.11.004. Epub 2024 Nov 20.

Abstract

Paclitaxel induces peripheral neuropathy, which is considered a dose-limiting factor. However, appropriate prophylactic agents are currently unavailable. We investigated the prophylactic effects of calmangafodipir, a superoxide dismutase mimetic, on paclitaxel-induced peripheral neuropathy using a male rat model. Repeated administration of paclitaxel (6 mg/kg, intraperitoneal, once weekly for 4 weeks) resulted in mechanical allodynia in the von Frey test and axonal degeneration in the sciatic nerve. Conversely, calmangafodipir (1-10 mg/kg, intravenous, thrice weekly for 4 weeks) prevented mechanical allodynia and axonal degeneration induced by paclitaxel. These results suggest that calmangafodipir may inhibit paclitaxel-induced peripheral neuropathy.

Keywords: Calmangafodipir; Paclitaxel; Peripheral neuropathy.

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic
  • Disease Models, Animal
  • Hyperalgesia / chemically induced
  • Male
  • Paclitaxel* / adverse effects
  • Peripheral Nervous System Diseases* / chemically induced
  • Rats
  • Rats, Sprague-Dawley
  • Sciatic Nerve / drug effects
  • Superoxide Dismutase* / metabolism

Substances

  • Paclitaxel
  • Superoxide Dismutase
  • Antineoplastic Agents, Phytogenic